300653 正海生物
已收盘 08-14 15:00:00
资讯
新帖
简况
正海生物:产品可吸收硬脑(脊)膜补片应用于神经外科
证券之星 · 08:45
正海生物:产品可吸收硬脑(脊)膜补片应用于神经外科
正海生物股价上涨1.05% 活性生物骨推广入院有序开展
金融界 · 08-11
正海生物股价上涨1.05% 活性生物骨推广入院有序开展
骨科材料概念盘中跳水,正海生物跌1.24%
市场透视 · 08-08
骨科材料概念盘中跳水,正海生物跌1.24%
【私募调研记录】正圆投资调研正海生物
证券之星 · 08-07
【私募调研记录】正圆投资调研正海生物
正海生物(300653)2025年中报简析:净利润减45.97%,三费占比上升明显
证券之星 · 08-06
正海生物(300653)2025年中报简析:净利润减45.97%,三费占比上升明显
正海生物股价跌至22.01元 上半年净利润下滑45.97%
金融界 · 08-05
正海生物股价跌至22.01元 上半年净利润下滑45.97%
正海生物(300653.SZ)发布上半年业绩,归母净利润4648.57万元,下降45.97%
智通财经 · 08-04
正海生物(300653.SZ)发布上半年业绩,归母净利润4648.57万元,下降45.97%
正海生物:活性生物骨具有促进局部骨缺损修复的能力
证券之星 · 07-30
正海生物:活性生物骨具有促进局部骨缺损修复的能力
正海生物:公司产品暂未应用于脑机接口领域
证券之星 · 06-24
正海生物:公司产品暂未应用于脑机接口领域
正海生物:未来公司将酌情考虑并购事项
证券之星 · 06-24
正海生物:未来公司将酌情考虑并购事项
骨科材料概念盘中跳水,正海生物跌1.02%
市场透视 · 06-13
骨科材料概念盘中跳水,正海生物跌1.02%
【牙科医疗板块盘初拉升】牙科医疗板块盘初拉升,皓宸医疗封板涨停,爱迪特涨超5%,康惠制药、悦心健康、正海生物、国瓷材料等均涨超2%。
金融界 · 06-09
【牙科医疗板块盘初拉升】牙科医疗板块盘初拉升,皓宸医疗封板涨停,爱迪特涨超5%,康惠制药、悦心健康、正海生物、国瓷材料等均涨超2%。
烟台正海生物科技股份有限公司申请I类会议
金融界 · 06-05
烟台正海生物科技股份有限公司申请I类会议
正海生物:2025年公司将聚焦主业积极推进各项经营业务高质量开展
证券之星 · 05-28
正海生物:2025年公司将聚焦主业积极推进各项经营业务高质量开展
正海生物:公司将酌情考虑并购事项,并积极履行信披义务
证券之星 · 05-22
正海生物:公司将酌情考虑并购事项,并积极履行信披义务
正海生物:公司的钙硅生物陶瓷骨修复材料拟用于颌骨缺损的填充和修复
证券之星 · 05-22
正海生物:公司的钙硅生物陶瓷骨修复材料拟用于颌骨缺损的填充和修复
【机构调研记录】华泰保兴基金调研正海生物、安集科技
证券之星 · 05-15
【机构调研记录】华泰保兴基金调研正海生物、安集科技
正海生物:口腔产品在民营机构的推广应用存在一定的入院流程
证券之星 · 05-14
正海生物:口腔产品在民营机构的推广应用存在一定的入院流程
正海生物:钙硅生物陶瓷骨修复材料的降解周期长于骨修复材料
证券 · 05-08
正海生物:钙硅生物陶瓷骨修复材料的降解周期长于骨修复材料
正海生物(300653)3月31日股东户数1.7万户,较上期减少1.12%
证券之星 · 04-21
正海生物(300653)3月31日股东户数1.7万户,较上期减少1.12%
加载更多
公司概况
公司名称:
烟台正海生物科技股份有限公司
所属行业:
专用设备制造业
上市日期:
2017-05-16
主营业务:
烟台正海生物科技股份有限公司的主营业务是生物再生材料的研发、生产与销售。公司的主要产品是口腔修复膜、可吸收硬脑(脊)膜补片、硬脑(脊)膜补片、皮肤修复膜、骨修复材料、活性生物骨、光固化复合树脂、自酸蚀粘接剂、窝沟封闭剂、磷酸酸试剂、外科用填塞海绵。公司历经20余年的发展,先后承担了国家“863计划”、国家火炬计划,是国家首批专精特新“小巨人”企业、国家知识产权示范企业、高新技术企业。
发行价格:
11.72
{"stockData":{"symbol":"300653","market":"SZ","secType":"STK","nameCN":"正海生物","latestPrice":22.01,"timestamp":1755155025000,"preClose":22.58,"halted":0,"volume":4818675,"delay":0,"changeRate":-0.0252,"floatShares":180000000,"shares":180000000,"eps":0.5283,"marketStatus":"已收盘","change":-0.57,"latestTime":"08-14 15:00:00","open":22.58,"high":22.62,"low":21.92,"amount":107000000,"amplitude":0.031,"askPrice":22.01,"askSize":8,"bidPrice":21.97,"bidSize":7,"shortable":0,"etf":0,"ttmEps":0.5283,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1755221400000},"marketStatusCode":5,"adr":0,"adjPreClose":22.58,"symbolType":"stock","openAndCloseTimeList":[[1755135000000,1755142200000],[1755147600000,1755154800000]],"highLimit":24.84,"lowLimit":20.32,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":180000000,"isCdr":false,"pbRate":4.76,"roa":"--","peRate":41.661935,"roe":"5.17%","epsLYR":0.75,"committee":0.631746,"marketValue":3962000000,"turnoverRate":0.0268,"status":1,"floatMarketCap":3962000000},"requestUrl":"/m/hq/s/300653","defaultTab":"news","newsList":[{"id":"2559490958","title":"正海生物:产品可吸收硬脑(脊)膜补片应用于神经外科","url":"https://stock-news.laohu8.com/highlight/detail?id=2559490958","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559490958?lang=zh_cn&edition=full","pubTime":"2025-08-14 16:45","pubTimestamp":1755161117,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)08月14日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,请问公司的脑膜系列产品能应用在人脑工程中吗?正海生物回复:您好!公司的产品可吸收硬脑(脊)膜补片、硬脑(脊)膜补片主要应用于神经外科,主要用于各种原因导致的硬脑(脊)膜缺损的修复。感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081400030874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0251","300653"],"gpt_icon":0},{"id":"2558666688","title":"正海生物股价上涨1.05% 活性生物骨推广入院有序开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2558666688","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558666688?lang=zh_cn&edition=full","pubTime":"2025-08-11 22:02","pubTimestamp":1754920954,"startTime":"0","endTime":"0","summary":"截至2025年8月11日15时,正海生物股价报22.19元,较前一交易日上涨1.05%。正海生物属于医疗器械板块,专注于生物再生材料的研发、生产与销售,主要产品包括口腔修复膜、生物膜等。公司在互动平台表示,活性生物骨的推广入院工作正有序开展,下半年将继续聚焦产品开发入院和上量。公司销售费用增长主要源于活性生物骨的市场推广及口腔领域的精准化营销,营收下滑则受口腔板块收入下降影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/11220252350040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300653","BK0046","BK0251"],"gpt_icon":0},{"id":"2557515972","title":"骨科材料概念盘中跳水,正海生物跌1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557515972","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557515972?lang=zh_cn&edition=full","pubTime":"2025-08-08 09:46","pubTimestamp":1754617607,"startTime":"0","endTime":"0","summary":"08月08日,骨科材料概念盘中跳水,截至09点46分,骨科材料概念整体指数下跌1.01%,报1731.140点。从个股上来看,该概念的成分股中,正海生物跌1.24%,奥精医疗、春立医疗、ST凯利跌幅居前。从资金上来看,截止发稿,骨科材料概念主力净流入为-5294.79万,其中康拓医疗受到资金热捧,主力净流入140.14万;拉长时间线来看,该板块近20日主力资金净流入-10.20亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808094647a47c0c0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808094647a47c0c0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688236","BK0046","01858","BK0251","300653","688613"],"gpt_icon":0},{"id":"2557586892","title":"【私募调研记录】正圆投资调研正海生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2557586892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557586892?lang=zh_cn&edition=full","pubTime":"2025-08-07 08:01","pubTimestamp":1754524883,"startTime":"0","endTime":"0","summary":"根据市场公开信息及8月6日披露的机构调研信息,知名私募正圆投资近期对1家上市公司进行了调研,相关名单如下:1)正海生物 调研纪要:正海生物在机构调研中表示,活性生物骨入院工作有序开展,销售体量环比持续提升,产品优势在于构建低剂量高效能骨再生系统。上半年公司收入下滑主要受口腔板块需求不旺、竞争激烈及产品价格走低影响。机构简介:深圳正圆投资2015年成立于深圳前海自贸区,并于当年获得私募证券投资基金牌照。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025080700006193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"gpt_icon":0},{"id":"2557583859","title":"正海生物(300653)2025年中报简析:净利润减45.97%,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2557583859","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557583859?lang=zh_cn&edition=full","pubTime":"2025-08-07 06:03","pubTimestamp":1754517799,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期正海生物发布2025年中报。截至本报告期末,公司营业总收入1.88亿元,同比下降5.14%,归母净利润4648.57万元,同比下降45.97%。本报告期正海生物三费占比上升明显,财务费用、销售费用和管理费用总和占总营收同比增幅达43.77%。筹资活动产生的现金流量净额变动幅度为48.61%,原因:分配股利减少。去年的净利率为37.07%,算上全部成本后,公司产品或服务的附加值极高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080700003148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653"],"gpt_icon":0},{"id":"2557592318","title":"正海生物股价跌至22.01元 上半年净利润下滑45.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557592318","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557592318?lang=zh_cn&edition=full","pubTime":"2025-08-05 22:55","pubTimestamp":1754405704,"startTime":"0","endTime":"0","summary":"正海生物股价报22.01元,较前一交易日下跌1.12元。开盘价为22.49元,最高触及22.51元,最低下探21.85元,成交量为95787手,成交金额2.12亿元。正海生物属于医疗器械板块,专注于再生医学相关产品的研发及产业化。公司披露2025年半年度报告显示,上半年实现营业收入1.88亿元,同比下降5.14%;归属于上市公司股东的净利润4648.57万元,同比下降45.97%。数据显示,正海生物当日主力资金净流出3672.62万元,近五日主力资金净流出4407.70万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/05225552230650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300653"],"gpt_icon":0},{"id":"2556780715","title":"正海生物(300653.SZ)发布上半年业绩,归母净利润4648.57万元,下降45.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556780715","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556780715?lang=zh_cn&edition=full","pubTime":"2025-08-04 17:49","pubTimestamp":1754300948,"startTime":"0","endTime":"0","summary":"智通财经APP讯,正海生物(300653.SZ)发布2025年半年度报告,该公司营业收入为1.88亿元,同比减少5.14%。归属于上市公司股东的净利润为4648.57万元,同比减少45.97%。归属于上市公司股东的扣除非经常性损益的净利润为4028.07万元,同比减少46.77%。基本每股收益为0.26元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1325415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300653"],"gpt_icon":0},{"id":"2555296099","title":"正海生物:活性生物骨具有促进局部骨缺损修复的能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2555296099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555296099?lang=zh_cn&edition=full","pubTime":"2025-07-30 11:37","pubTimestamp":1753846636,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物07月30日在投资者关系平台上答复投资者关心的问题。2006年针对留尼汪180名患者前瞻性研究显示,感染后36个月,60%患者仍然存在关节痛。出现慢性关节痛的原因是骨侵蚀、关节间隙狭窄及滑膜增生。谢谢正海生物回复:您好,公司的活性生物骨具有促进局部骨缺损修复的能力,适用于填充由于创伤或手术造成的、不影响骨结构稳定性的骨缺损。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073000016120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"gpt_icon":0},{"id":"2545947506","title":"正海生物:公司产品暂未应用于脑机接口领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2545947506","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545947506?lang=zh_cn&edition=full","pubTime":"2025-06-24 11:34","pubTimestamp":1750736040,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:你好董秘,贵司有很多创新产品,其中有可以辅助脑机接口手术的产品么?比如手术过程中止血以及骨修复产品?如果没有有没有这方面发展研究趋势?正海生物回复:您好,公司已上市产品中活性生物骨主要应用于骨科,骨修复材料主要应用于口腔领域,二者暂未应用于脑机接口领域,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062400015016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"gpt_icon":0},{"id":"2545210475","title":"正海生物:未来公司将酌情考虑并购事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2545210475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545210475?lang=zh_cn&edition=full","pubTime":"2025-06-24 11:33","pubTimestamp":1750736039,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:1.公司有并购重组计划吗?2.公司在手订单跟去年有什么变化?正海生物回复:您好,公司的销售模式以现货销售模式为主,销量实现同比增长;未来公司将酌情考虑并购事项,并积极履行信披义务。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062400015011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"gpt_icon":0},{"id":"2543527489","title":"骨科材料概念盘中跳水,正海生物跌1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2543527489","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543527489?lang=zh_cn&edition=full","pubTime":"2025-06-13 09:51","pubTimestamp":1749779517,"startTime":"0","endTime":"0","summary":"06月13日,骨科材料概念盘中跳水,截至09点51分,骨科材料概念整体指数下跌1.02%,报1466.660点。从个股上来看,该概念的成分股中,正海生物跌1.02%,春立医疗、万邦德、ST凯利跌幅居前。从资金上来看,截止发稿,骨科材料概念主力净流入为-4368.46万,其中三友医疗受到资金热捧,主力净流入134.97万;拉长时间线来看,该板块近20日主力资金净流入-6.41亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613095157977d7174&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613095157977d7174&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688085","BK0046","688236","BK0251","300653"],"gpt_icon":0},{"id":"2542873852","title":"【牙科医疗板块盘初拉升】牙科医疗板块盘初拉升,皓宸医疗封板涨停,爱迪特涨超5%,康惠制药、悦心健康、正海生物、国瓷材料等均涨超2%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542873852","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542873852?lang=zh_cn&edition=full","pubTime":"2025-06-09 09:35","pubTimestamp":1749432930,"startTime":"0","endTime":"0","summary":"牙科医疗板块盘初拉升,皓宸医疗封板涨停,爱迪特涨超5%,康惠制药、悦心健康、正海生物、国瓷材料等均涨超2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/09093550938813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0235","603139","BK0138","BK0239","BK0070","BK0095","002622","BK0114","002162","IE0005HP3H50.USD","BK0224","301580","BK0046","BK0055","BK0132","BK0139","BK0028","BK0251","300285","BK0021","BK0229","IE0034224299.USD","300653","BK0053","159891"],"gpt_icon":0},{"id":"2541009800","title":"烟台正海生物科技股份有限公司申请I类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2541009800","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541009800?lang=zh_cn&edition=full","pubTime":"2025-06-06 04:44","pubTimestamp":1749156298,"startTime":"0","endTime":"0","summary":"金融界6月6日消息,据CDE官网沟通交流公示,于6月6日收到烟台正海生物科技股份有限公司申请的“I类会议”,当前状态“处理中”。烟台正海生物科技股份有限公司,成立于2003年,位于烟台市,是一家以从事医药制造业为主的企业。通过天眼查大数据分析,烟台正海生物科技股份有限公司共对外投资了2家企业,参与招投标项目317次,专利信息104条,此外企业还拥有行政许可45个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/06044450888049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0046","BK0251","300653"],"gpt_icon":0},{"id":"2538415407","title":"正海生物:2025年公司将聚焦主业积极推进各项经营业务高质量开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2538415407","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538415407?lang=zh_cn&edition=full","pubTime":"2025-05-28 08:45","pubTimestamp":1748393129,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)05月27日在投资者关系平台上答复投资者关心的问题。投资者提问:今年的营收展望?正海生物回复:您好!2025年公司将聚焦主业,积极推进各项经营业务高质量开展,不断提升销售体量,有信心实现可持续发展。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052800005751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300653","BK0046"],"gpt_icon":0},{"id":"2537296915","title":"正海生物:公司将酌情考虑并购事项,并积极履行信披义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2537296915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537296915?lang=zh_cn&edition=full","pubTime":"2025-05-22 17:03","pubTimestamp":1747904592,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问:同为再生医学赛道,迈普医学拟收购易介医疗51%股权,在利率如此低且未来依旧有更低利率预期背景下,公司却将绝大多数现金流用于理财产品固定存款是否有点儿不思进取?是否考虑收购并购同赛道或相近赛道公司计划?正海生物回复:您好,公司将酌情考虑并购事项,并积极履行信披义务。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200025665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"gpt_icon":0},{"id":"2537290915","title":"正海生物:公司的钙硅生物陶瓷骨修复材料拟用于颌骨缺损的填充和修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2537290915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537290915?lang=zh_cn&edition=full","pubTime":"2025-05-22 17:03","pubTimestamp":1747904591,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物05月22日在投资者关系平台上答复投资者关心的问题。与题目中的产品均有差异,感谢您的关注!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200025664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0251","300653"],"gpt_icon":0},{"id":"2535924887","title":"【机构调研记录】华泰保兴基金调研正海生物、安集科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2535924887","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535924887?lang=zh_cn&edition=full","pubTime":"2025-05-15 08:02","pubTimestamp":1747267339,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及5月14日披露的机构调研信息,华泰保兴基金近期对2家上市公司进行了调研,相关名单如下:1)正海生物 调研纪要:正海生物在口腔行业面临竞争加剧的情况下,将通过巩固种植领域优势、精准化营销和产品升级来应对。华泰保兴基金成立于2016年,截至目前,资产管理规模589.61亿元,排名77/210;资产管理规模521.28亿元,排名71/210;管理公募基金数58只,排名92/210;旗下公募基金经理12人,排名97/210。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051500005040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0214","BK0046","688019","300653"],"gpt_icon":0},{"id":"2535058123","title":"正海生物:口腔产品在民营机构的推广应用存在一定的入院流程","url":"https://stock-news.laohu8.com/highlight/detail?id=2535058123","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535058123?lang=zh_cn&edition=full","pubTime":"2025-05-14 08:54","pubTimestamp":1747184096,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)05月14日在投资者关系平台上答复投资者关心的问题。投资者提问:请问钙硅生物陶瓷上市后在民营口腔机构,是否存在入院步骤,能否快速替代公司一代产品胶原骨粉份额?从上市到民营机构中销售需要哪些步骤或手续?正海生物回复:您好,口腔产品在民营机构的推广应用存在一定的入院流程,包括产品试用、产品介绍及培训、价格谈判等。相较于公立医院的流程,民营的程序相对简便、周期更短。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051400006873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"gpt_icon":0},{"id":"2533393881","title":"正海生物:钙硅生物陶瓷骨修复材料的降解周期长于骨修复材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2533393881","media":"证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533393881?lang=zh_cn&edition=full","pubTime":"2025-05-08 20:39","pubTimestamp":1746707940,"startTime":"0","endTime":"0","summary":"证券日报网讯正海生物5月8日在互动平台回答投资者提问时表示,降解周期与评价方案有关,经研究表明,钙硅生物陶瓷骨修复材料的降解周期长于骨修复材料。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-05-08/doc-inevwiqp2344010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0251","300653"],"gpt_icon":0},{"id":"2529201228","title":"正海生物(300653)3月31日股东户数1.7万户,较上期减少1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529201228","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529201228?lang=zh_cn&edition=full","pubTime":"2025-04-21 17:21","pubTimestamp":1745227266,"startTime":"0","endTime":"0","summary":"证券之星消息,近日正海生物披露,截至2025年3月31日公司股东户数为1.7万户,较12月31日减少193.0户,减幅为1.12%。在医疗器械行业个股中,正海生物股东户数低于行业平均水平,截至3月31日,医疗器械行业平均股东户数为2.09万户。从股价来看,2024年12月31日至2025年3月31日,正海生物区间涨幅为5.54%,在此期间股东户数减少193.0户,减幅为1.12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042100022782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1755205312982,"stockEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0521},{"period":"3month","weight":0.1279},{"period":"6month","weight":0.0725},{"period":"1year","weight":0.11},{"period":"ytd","weight":0.0574}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":0.0461},{"period":"3month","weight":0.0888},{"period":"6month","weight":0.0955},{"period":"1year","weight":0.2862},{"period":"ytd","weight":0.0939}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台正海生物科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"16815人(较上一季度减少0.89%)","perCapita":"10704股","listingDate":"2017-05-16","address":"山东省烟台市福山区经济技术开发区南京大街7号","registeredCapital":"18000万元","survey":" 烟台正海生物科技股份有限公司的主营业务是生物再生材料的研发、生产与销售。公司的主要产品是口腔修复膜、可吸收硬脑(脊)膜补片、硬脑(脊)膜补片、皮肤修复膜、骨修复材料、活性生物骨、光固化复合树脂、自酸蚀粘接剂、窝沟封闭剂、磷酸酸试剂、外科用填塞海绵。公司历经20余年的发展,先后承担了国家“863计划”、国家火炬计划,是国家首批专精特新“小巨人”企业、国家知识产权示范企业、高新技术企业。","listedPrice":11.72},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.7","shortVersion":"4.34.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"正海生物(300653)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供正海生物(300653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"正海生物,300653,正海生物股票,正海生物股票老虎,正海生物股票老虎国际,正海生物行情,正海生物股票行情,正海生物股价,正海生物股市,正海生物股票价格,正海生物股票交易,正海生物股票购买,正海生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"正海生物(300653)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供正海生物(300653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}